Viridian Therapeutics, Inc.
$14.68
▼
-1.62%
2026-04-21 10:10:00
www.viridiantherapeutics.com
NCM: VRDN
Explore Viridian Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.5 B
Current Price
$14.68
52W High / Low
$34.29 / $11.76
Stock P/E
—
Book Value
$5.79
Dividend Yield
—
ROCE
-43.85%
ROE
-49.16%
Face Value
—
EPS
$-3.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
252
Beta
1.17
Debt / Equity
7.28
Current Ratio
12.65
Quick Ratio
12.65
Forward P/E
-6.66
Price / Sales
21.57
Enterprise Value
$837.99 M
EV / EBITDA
-2.31
EV / Revenue
11.83
Rating
Strong Buy
Target Price
$35
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 2. | Solid Biosciences Inc. | $8.49 | — | $835.34 M | — | -90.02% | -1.1% | $8.87 / $2.41 | $2.28 |
| 3. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
| 4. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 5. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
| 6. | Protara Therapeutics, Inc. | $5.3 | — | $286.65 M | — | -32.51% | -31.6% | $7.82 / $2.77 | $3.67 |
| 7. | Eupraxia Pharmaceuticals Inc. | $7.2 | — | $599.04 M | — | -47.73% | -68.76% | $12.86 / $4.38 | $1.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0.13 M | 70.57 M | 0.07 M | 0.07 M | 0.07 M |
| Operating Profit | -122.75 M | -40.01 M | -106.77 M | -93.87 M | -87.47 M |
| Net Profit | -120.36 M | -34.6 M | -100.73 M | -86.91 M | -79.72 M |
| EPS in Rs | -1.18 | -0.34 | -0.99 | -0.85 | -0.78 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 70.85 M | 0.3 M | 0.31 M | 1.77 M |
| Operating Profit | -363.39 M | -299.04 M | -254.45 M | -134.3 M |
| Net Profit | -342.6 M | -269.95 M | -237.73 M | -129.87 M |
| EPS in Rs | -3.35 | -2.64 | -2.33 | -1.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 899.42 M | 742.4 M | 490.42 M | 435.09 M |
| Total Liabilities | 177.25 M | 70.76 M | 48.4 M | 40.03 M |
| Equity | 722.17 M | 671.64 M | 442.02 M | 395.06 M |
| Current Assets | 894.23 M | 738.46 M | 486.48 M | 431.17 M |
| Current Liabilities | 70.7 M | 47.87 M | 26.64 M | 33.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -276.39 M | -232.32 M | -184.17 M | -93.84 M |
| Investing CF | -37.56 M | -228.65 M | -94.25 M | -115.13 M |
| Financing CF | 426.74 M | 457.74 M | 225.67 M | 322.24 M |
| Free CF | -276.89 M | -232.83 M | -185.07 M | -94.64 M |
| Capex | -0.49 M | -0.51 M | -0.9 M | -0.8 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -3.82% | -82.28% | — | — |
| Earnings Growth % | -13.55% | -83.05% | — | — |
| Profit Margin % | -89387.09% | -75711.46% | -7329.23% | — |
| Operating Margin % | -99018.21% | -81035.03% | -7579.23% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -88480.79% | -75121.34% | -7287.42% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.